Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
A phase 3 trial of Talazoparib and Enzalutamide in prostate cancer, run by Pfizer, active and no longer recruiting.
Overview
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC is a phase 3 interventional study registered as NCT04821622 by Pfizer, with 599 participants enrolled, started 2021-05-12 and due to reach its primary completion in 2026-02-18. Interventions recorded: talazoparib plus enzalutamide and Placebo plus enzalutamide.
Similar pages
not linked directly; found by shared links- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
- TrialSymbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
- TrialEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
- TrialA Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Shares Astellas and the tag pipeline.
- TrialA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Shares Enzalutamide, Prostate cancer and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Shares Astellas and the tag pipeline.
- TreatmentPF-07248144
Shares Pfizer (incl. Seagen), Prostate cancer and the tag pipeline.